Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | RARB | P10826 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.31 |
| ▸ | KDM4A | O75164 | 1/20 | 0.31 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.31 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
| ▸ | FUT7 | Q11130 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8443203 | 1.00 | LMNA (0.39) | LMNARARBALDH1A1KDM4CKDM4A | |
| SCHEMBL2110048 | 1.00 | LMNA (0.39) | LMNARARBALDH1A1KDM4CKDM4A | |
| SCHEMBL8811504 | 1.00 | LMNA (0.39) | LMNARARBALDH1A1KDM4CKDM4A | |
| SCHEMBL93134 | 1.00 | LMNA (0.39) | LMNARARBALDH1A1KDM4CKDM4A | |
| SCHEMBL93187 | 1.00 | LMNA (0.39) | LMNARARBALDH1A1KDM4CKDM4A | |
| SCHEMBL2110029 | 1.00 | LMNA (0.39) | LMNARARBALDH1A1KDM4CKDM4A | |
| SCHEMBL93166 | 1.00 | LMNA (0.39) | LMNARARBALDH1A1KDM4CKDM4A | |
| SCHEMBL2109724 | 1.00 | LMNA (0.39) | LMNARARBALDH1A1KDM4CKDM4A | |
| SCHEMBL2109678 | 1.00 | LMNA (0.39) | LMNARARBALDH1A1KDM4CKDM4A | |
| SCHEMBL5145733 | 1.00 | LMNA (0.39) | LMNARARBALDH1A1KDM4CKDM4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024096066-A1 | CYCLIC PEPTIDE DERIVATIVE COMPOSITION FOR TREATING OR PREVENTING CENTRAL NERVOUS SYSTEM INJURY/DISEASE | 第一工業製薬株式会社 | 2024-05-10 | — | — | WO | disclosed |
| WO-2024096067-A1 | CYCLIC PEPTIDE DERIVATIVE COMPOSITION FOR TREATING OR PREVENTING NEUROPATHIC PAIN AND/OR INFLAMMATORY PAIN | 第一工業製薬株式会社 | 2024-05-10 | — | — | WO | disclosed |
| WO-2024071370-A1 | CYCLIC PEPTIDE DERIVATIVE COMPOSITION FOR TREATING OR PREVENTING EYE DISEASE | 第一工業製薬株式会社 | 2024-04-04 | — | — | WO | disclosed |
| WO-2024029630-A1 | CYCLIC PEPTIDE DERIVATIVE, METHOD FOR PRODUCING SAME, AND COMPOSITION | 第一工業製薬株式会社 | 2024-02-08 | — | — | WO | disclosed |
| EP-1903069-B1 | NOVEL POLYMER AND METHOD OF MEASURING CHOLESTEROL THEREWITH | WAKO PURE CHEM IND LTD (JP) | 2015-08-12 | — | — | EP | disclosed |
| EP-2821395-A2 | Novel disulfonic acid ester as an additive for an electrolyte for a lithium secondary battery | Wako Pure Chemical Industries, Ltd. (JP) | 2015-01-07 | — | — | EP | disclosed |
| US-8716513-B2 | Process for production of bis-quaternary ammonium salt, and novel intermediate | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2014-05-06 | — | — | US | disclosed |
| EP-2463266-A1 | PROCESS FOR PRODUCTION OF BIS-QUATERNARY AMMONIUM SALT, AND NOVEL INTERMEDIATE | Wako Pure Chemical Industries, Ltd. (JP) | 2012-06-13 | — | — | EP | disclosed |
| US-20120130107-A1 | PROCESS FOR PRODUCTION OF BIS-QUATERNARY AMMONIUM SALT, AND NOVEL INTERMEDIATE | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2012-05-24 | — | — | US | disclosed |
| US-8158375-B2 | Polymer and method of measuring cholesterol therewith | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2012-04-17 | — | — | US | disclosed |
| EP-2239281-A2 | Novel polymer and method for determining cholesterol using the same | Wako Pure Chemical Industries, Ltd. (JP) | 2010-10-13 | — | — | EP | disclosed |
| US-20090215097-A1 | Novel Polymer and Method of Measuring Cholesterol Therewith | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2009-08-27 | — | — | US | disclosed |
| EP-1903069-A1 | NOVEL POLYMER AND METHOD OF MEASURING CHOLESTEROL THEREWITH | Wako Pure Chemical Industries, Ltd. (JP) | 2008-03-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120130107-A1 | PROCESS FOR PRODUCTION OF BIS-QUATERNARY AMMONIUM SALT, AND NOVEL INTERMEDIATE | ASS1, C1S, FHIT | LMNA 4498/4885RARB 1465/4885ALDH1A1 799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.